Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial

Advanced Breast Cancer ◽

Study Protocol ◽

Hormone Receptor ◽

Controlled Trial ◽

Advanced Breast ◽

Optimal Position ◽

Randomized Controlled ◽

Symptom response analysis of a randomized controlled trial of reflexology for symptom management among women with advanced breast cancer

Supportive Care in Cancer ◽

10.1007/s00520-019-04959-y ◽

2019 ◽

Vol 28 (3) ◽

pp. 1395-1404

Author(s):

Alla Sikorskii ◽

Pratim Guha Niyogi ◽

David Victorson ◽

Deimante Tamkus ◽

Gwen Wyatt

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Symptom Management ◽

Controlled Trial ◽

Advanced Breast ◽

Response Analysis ◽

Randomized Controlled ◽

Symptom Response

Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials

Breast Cancer Research and Treatment ◽

10.1007/s10549-020-05551-3 ◽

2020 ◽

Vol 180 (2) ◽

pp. 269-278

Author(s):

Meng Li ◽

Yiting Xiong ◽

Chen Liao ◽

Yunyan He ◽

Sijia Duan ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Randomized Controlled Trials ◽

Hormone Receptor ◽

Meta Analysis ◽

Advanced Breast ◽

Controlled Trials ◽

Randomized Controlled ◽

Randomized controlled trial of late-course concurrent versus sequential chemoradiotherapy after mastectomy and axillary surgery in locally advanced breast cancer

Medicine ◽

10.1097/md.0000000000008252 ◽

2017 ◽

Vol 96 (41) ◽

pp. e8252 ◽

Cited By ~ 1

Author(s):

Ying Lu ◽

Haixin Huang ◽

Hui Yang ◽

Dagui Chen

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Controlled Trial ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Advanced Breast ◽

Axillary Surgery ◽

Randomized Controlled

Abstract OT3-02-04: Selecting the optimal position of CDK4/6 inhibitors in hormone-receptor-positive advanced breast cancer: The BOOG 2017-03 SONIA study

10.1158/1538-7445.sabcs18-ot3-02-04 ◽

2019 ◽

Author(s):

A van Ommen - Nijhof ◽

A van der Voort ◽

IR Konings ◽

A Jager ◽

GS Sonke ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Optimal Position ◽

Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial

Chinese Journal of Cancer ◽

10.1186/s40880-017-0196-5 ◽

2017 ◽

Vol 36 (1) ◽

Cited By ~ 7

Author(s):

Qiu-Wen Tan ◽

Ting Luo ◽

Hong Zheng ◽

Ting-Lun Tian ◽

Ping He ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Controlled Trial ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Advanced Breast ◽

Combination Regimen ◽

Randomized Controlled

Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer

BMC Cancer ◽

10.1186/1471-2407-13-239 ◽

2013 ◽

Vol 13 (1) ◽

Cited By ~ 10

Author(s):

Yutaka Yamamoto ◽

Takashi Ishikawa ◽

Yasuo Hozumi ◽

Masahiko Ikeda ◽

Hiroji Iwata ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Controlled Trial ◽

Metastatic Breast ◽

Randomized Controlled ◽

Abstract P1-14-01: Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior non-steroidal aromatase inhibitor treatment in postmenopausal women with hormone receptor-positive metastatic breast cancer (Hi-FAIR ex study)

10.1158/0008-5472.sabcs13-p1-14-01 ◽

2013 ◽

Author(s):

Y Yamamoto ◽

T Ishikawa ◽

Y Hozumi ◽

M Ikeda ◽

N Kondo ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Hormone Receptor ◽

Controlled Trial ◽

Metastatic Breast ◽

Randomized Controlled ◽

Hormone Receptor Positive ◽

Aromatase Inhibitor Treatment ◽

Inhibitor Treatment

Ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who received no prior therapy for advanced disease

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0036-1592812 ◽

2016 ◽

Vol 76 (10) ◽

Author(s):

EM Grischke ◽

A Nusch ◽

N Marschner ◽

W Abenhardt ◽

J Wilke ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Advanced Disease ◽

Advanced Breast ◽

Prior Therapy ◽

PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer

Contemporary Clinical Trials Communications ◽

10.1016/j.conctc.2018.05.012 ◽

2018 ◽

Vol 10 ◽

pp. 190-192

Author(s):

Filipa Lynce ◽

Mervat Saleh ◽

Ayesha Shajahan-Haq ◽

Christopher Gallagher ◽

Asma Dilawari ◽

...

Keyword(s):

Breast Cancer ◽

African American ◽

Advanced Breast Cancer ◽

African American Women ◽

Phase Ii ◽

Hormone Receptor ◽

Advanced Breast ◽

Safety Study ◽

American Women ◽

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Annals of Oncology ◽

10.1093/annonc/mdu009 ◽

2014 ◽

Vol 25 (4) ◽

pp. 808-815 ◽

Cited By ~ 87

Author(s):

H.S. Rugo ◽

K.I. Pritchard ◽

M. Gnant ◽

S. Noguchi ◽

M. Piccart ◽

...

Keyword(s):

Breast Cancer ◽

Adverse Events ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Time Course ◽

Advanced Breast ◽